Abstract
Background This study discusses the anti-inflammatory mechanism of Yiqi Huayu Jiedu decoction (YQHYJD) and studies the intervening effect of YQHYJD on the inflammatory cytokines in acute respiratory distress syndrome (ARDS) rats by inhibiting the TLR4/NLRP3 signal pathway. The aim of the probe is to provide evidence to support the identification of therapeutic targets in Chinese medicine treatment, which broadens the alternatives for the treatment of ARDS. Method A lipopolysaccharide (LPS)-induced ARDS model group is established on rats by tail vein injection. A medicine group is established on ARDS rats by prophylactic administration using YQHYJD. Materials are collected, and tests are conducted according to experimental processes. Result The rats in the medicine group gained weight compared with those in the ARDS model group. Pathological sections from the medicine group indicated improved condition in terms of pulmonary and interstitial edema in the lung tissues of rats compared with that from the ARDS model group. The percentage of neutrophil of the medicine group was significantly brought down compared with that of the ARDS model group (P < 0.001). Enzyme-linked immunosorbent assay (ELISA) was used to detect the changes in the level of inflammatory cytokines. It was observed that the levels of IL-1β and IL-18 in serum of the medicine group significantly decreased (P < 0.001 and P < 0.01), the contents of TLR4 and NLRP3 in bronchoalveolar lavage fluid (BALF) of the medicine group decreased, and the contents of TLR4 and NLRP3 in lung tissue homogenate of the medicine group significantly decreased (P < 0.05, P < 0.001, P < 0.01, and P < 0.05). In further mass spectrum identification of the proteins from the same animal groups, it was observed that the expressions of inflammatory proteins TNFRSF1, LBP, and NOS2 of the medicine group were reduced. The differences were statistically significant. Conclusions The pharmacological action of YQHYJD's anti-inflammatory mechanism is closely associated with the regulation of inflammatory cytokines TLR4, NLRP3, IL-1β, IL-18, TNFRSF1, LBP, and NOS2 on the TLR4/NLRP3 signal pathway.
Highlights
Acute respiratory distress syndrome (ARDS) is an acute respiratory disease that induces hypoxemia and pulmonary edema due to increased permeability of alveolar capillaries.e characteristics of ARDS include blurred shadows on both lungs caused by noncardiogenic pulmonary edema accompanied by severe hypoxemia [1]
ARDS Rats Conditions. e experimental animal model was an acute lung injury model related to LPS-induced pyemia. e time duration of the experimental process was relatively short. e control group demonstrated insignificant changes during the experiment with a good mental state, agility and freedom in movement, and bright and softsmooth hair. e model group started to show deteriorating mental conditions, reduced movement, slow in reaction, sleep-prone languor, withered and yellow hair lacking in luster, cyanosis in lips and claws, and unformed stool. e medicine group demonstrated similar but relatively lighter conditions compared to the model group
Compared with ARDS treatment using a single blocker, this study studied the integrated regulating effect of Yiqi Huayu Jiedu decoction (YQHYJD) on the TLR4/NLRP3 pathway in ARDS treatment. e micromechanism of traditional Chinese medicine compound was thoroughly explored. is innovative research provided evidence for the identification of therapeutic targets in ARDS treatment using Chinese medicine therapy, introducing a novel approach for the treatment of ARDS
Summary
Acute respiratory distress syndrome (ARDS) is an acute respiratory disease that induces hypoxemia and pulmonary edema due to increased permeability of alveolar capillaries.e characteristics of ARDS include blurred shadows on both lungs caused by noncardiogenic pulmonary edema accompanied by severe hypoxemia [1]. Acute respiratory distress syndrome (ARDS) is an acute respiratory disease that induces hypoxemia and pulmonary edema due to increased permeability of alveolar capillaries. E COVID-19 pandemic in 2019 was extremely contagious, and patients with critical conditions would develop into ARDS followed by death, making it a pressing challenge in the research of respiratory diseases to discover effective treatment approaches against ARDS. Major Western medicine therapies against ARDS include the treatment of primary disease, oxygen therapy, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), drug therapy, and the use of the neuromuscular blocking agent. E clinical drug therapy includes the use of glucocorticoid, activated protein C, antiendotoxin antibody, interferon, and pulmonary surfactant. It is usually difficult for a single symptomatic preparation to deliver ideal clinical results [1]. Meta-analysis indicates [5] that an integrated Chinese traditional and Western medicine therapy presents a promising advantage in bringing down mortality
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
